After Complex Sale, Amira Scientist And VC Team Up Again For Discovery Start-up
This article was originally published in The Pink Sheet Daily
Versant Ventures is backing Inception Sciences, a new company led by former Amira chief scientist Peppi Prasit that aims to spin out multiple programs into separate companies, a new model gaining traction in the biotech world.
You may also be interested in...
Versant is betting a sizable amount of its portfolio on drug assets, instead of full-blown companies, with single buyers holding options to acquire each one.
Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”
As VCs experiment with new models for single-asset companies, new entrant NeXeption is trying something similar without raising its own fund. Can it wring enough value from the best assets pharmas are neglecting, without giving too much back to their original owners?